Scalper1 News
Biotechs The Medicines Co. (MDCO) and Alnylam Pharmaceuticals (ALNY) both got multiple price target increases Monday after they announced positive data on their anti-cholesterol drug candidate over the weekend. At the annual congress of the European Society of Cardiology, Medicines Co. and Alnylam presented results of their phase-one trial of ALN-PCSsc, which divided subjects with high LDL cholesterol (LDL-C) into various different dosage groups, Scalper1 News
Scalper1 News